Drug details

Darzalex Faspro (daratumumab and hyaluronidase-fihj injection)

type of Antineoplastics, Anti-CD38 Monoclonal Antibodies

Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of a CD38-directed cytolytic antibody and an endoglycosidase used to treat adult patients with multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.

The drug is often used to treat Multiple myeloma .

This drug may have the following side effects:

• Serious allergic reactions and other severe injection-related reactions.

The following drugs are related to Darzalex Faspro, either as a replacement or used together:

• Abecma (idecabtagene vicleucel suspension)
• Adriamycin PFS (doxorubicin hydrochloride)
• Treanda (bendamustine hydrochloride injection)
• Cytoxan (cyclophosphamide)
• Doxil (doxorubicin hcl liposome injection)
• Jaypirca (pirtobrutinib tablets)
• Talvey (talquetamab-tgvs injection)
• Tecvayli (teclistamab-cqyv injection)
• Vincristine Sulfate Injection (vincristine sulfate)